Tenecteplase in Ischemic Stroke: Challenge and Opportunity.

ABSTRACT:

Purpose of review

Intravenous thrombolysis is the first-line therapy for ischemic stroke, and alteplase has been used as an intravenous thrombolysis drug for over 20 years. However, considering its low rate of recanalization and risk of intracerebral hemorrhage, alteplase may not be the optimal thrombolytic drug of choice for ischemic stroke. Tenecteplase (TNK) is a genetically engineered, mutant, tissue plasminogen activator that is a potential substitute to alteplase in ischemic stroke. The pharmacokinetic advantages of TNK include greater fibrin selectivity than alteplase and prolonged half-life time. In this review, we have summarized the clinical trials of TNK in ischemic stroke.

Recent findings

Clinical trials showed a higher recanalization rate of TNK over alteplase w

SUBMITTER: Li G 

PROVIDER: S-EPMC9109727 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature